Sponsors (4)
The bill strengthens research, oversight, data-sharing, and funded services to improve diagnosis and care for veterans with blast-related brain conditions, at the cost of modest federal spending and added administrative burdens and timeline risks.
Veterans (and active military) receive expanded coverage, research focus, and improved VA–DoD data sharing that together improve diagnosis, treatment, and coordinated care for repetitive low-level blast exposure, dementia, and other service-related brain conditions.
Independent research coordination and oversight by the National Academies (NASEM) with regular reports to Congress increases scientific rigor, validation of biomarkers, and accountability for the program.
Provides predictable funding ($5 million per year from FY2025–2034) to sustain research, implementation, and quality-improvement activities supporting affected veterans and health systems.
Taxpayers are exposed to up to $50 million in authorized spending over FY2025–2034, which could crowd out other federal priorities.
VA and DoD (and participating health systems) must allocate staff and IT resources to build and maintain the open data platform and data-sharing partnership, creating administrative burdens and ongoing costs.
Tight mandated timelines (e.g., rapid NASEM contracting and biennial reporting) could strain implementation and produce preliminary or rushed findings before long-term effects are clear.
Based on analysis of 2 sections of legislative text.
Introduced February 27, 2025 by Jerry Moran · Last progress February 27, 2025
Expands and funds a VA research initiative to study brain health in veterans by broadening covered conditions, requiring VA–DoD data sharing on an open platform, and directing targeted research on repetitive low-level blast exposure. It mandates the VA to contract with the National Academies (NASEM) within 60 days to validate biomarkers and to produce regular reports to Congress, and authorizes $5,000,000 per year for fiscal years 2025–2034 to support the initiative.